Associations among gut permeability, inflammatory markers, and symptoms in patients with irritable bowel syndrome

Journal of Gastroenterology

Volumn 49, Issue 11, 2014, Pages 1467-1476

  Shulman, Robert J ^a   Jarrett, Monica E ^b   Cain, Kevin C ^b   Broussard, Elizabeth K ^b   Heitkemper, Margaret M ^b  

^a TEXAS CHILDREN S HOSPITAL   (United States)

^b UNIVERSITY OF WASHINGTON   (United States)

Author keywords

Cytokine; Irritable bowel syndrome; Permeability; Symptoms

Indexed keywords

INTERLEUKIN 10; LACTULOSE; MANNITOL; MARKER; SUCROSE; BIOLOGICAL MARKER; IL10 PROTEIN, HUMAN;

ABDOMINAL PAIN; ADULT; AGED; ANXIETY; ARTICLE; BLOOD; CONTROLLED STUDY; DEPRESSION; DISEASE ASSOCIATION; DISTRESS SYNDROME; FEMALE; HUMAN; INTESTINE MUCOSA PERMEABILITY; IRRITABLE COLON; MAJOR CLINICAL STUDY; MALE; MONOCYTE; PERIPHERAL BLOOD MONONUCLEAR CELL; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SCORING SYSTEM; SUPERNATANT; ADOLESCENT; DAILY LIFE ACTIVITY; IMMUNOLOGY; INTESTINE MUCOSA; MENTAL STRESS; METABOLISM; MIDDLE AGED; MONONUCLEAR CELL; PATHOPHYSIOLOGY; PERMEABILITY; PROSPECTIVE STUDY; PSYCHOLOGY; RETROSPECTIVE STUDY; SELF REPORT; SEVERITY OF ILLNESS INDEX; YOUNG ADULT;

ABDOMINAL PAIN; ACTIVITIES OF DAILY LIVING; ADOLESCENT; ADULT; AGED; BIOMARKERS; FEMALE; HUMANS; INTERLEUKIN-10; INTESTINAL MUCOSA; IRRITABLE BOWEL SYNDROME; LEUKOCYTES, MONONUCLEAR; MALE; MIDDLE AGED; PERMEABILITY; PROSPECTIVE STUDIES; RETROSPECTIVE STUDIES; SELF REPORT; SEVERITY OF ILLNESS INDEX; STRESS, PSYCHOLOGICAL; YOUNG ADULT;

EID: 84926666952     PISSN: 09441174     EISSN: 14355922     Source Type: Journal    
DOI: 10.1007/s00535-013-0919-6     Document Type: Article

References (42)

1. Maxion-Bergemann S, Thielecke F, Abel F, Bergemann R. Costs of irritable bowel syndrome in the UK and US. Pharmacoeconomics. 2006;24(1):21-37.
2. Agarwal N, Spiegel BM. The effect of irritable bowel syndrome on health-related quality of life and health care expenditures. Gastroenterol Clin North Am. 2011;40(1):11-9.
3. Graham DP, Savas L, White D, El-Serag R, Laday-Smith S, Tan G, et al. Irritable bowel syndrome symptoms and health related quality of life in female veterans. Aliment Pharmacol Ther. 2010;31(2):261-73.
4. Drossman D, Corazziari E, Delvaux M, Spiller R, Talley N, Thompson W, et al. Rome III: the functional gastrointestinal disorders. 3rd ed. McLean: Degnon Associates; 2006.
5. Qin HY, Wu JC, Tong XD, Sung JJ, Xu HX, Bian ZX. Systematic review of animal models of post-infectious/post-inflammatory irritable bowel syndrome. J Gastroenterol. 2011;46(2):164-74.
6. Stasi C, Rosselli M, Bellini M, Laffi G, Milani S. Altered neuroendocrine-immune pathways in the irritable bowel syndrome: the top-down and the bottom-up model. J Gastroenterol. 2012;47(11):1177-85.
7. Adam B, Tsopelas C, Liebregts T, Bartholomeusz FD, Holtmann G. Host immune response determines visceral hyperalgesia in a rat model of post-inflammatory irritable bowel syndrome. J Gastroenterol. 2013;48(10):1119-27.
8. Ford AC, Talley NJ. Mucosal inflammation as a potential etiological factor in irritable bowel syndrome: a systematic review. J Gastroenterol. 2011;46(4):421-31.
9. Matricon J, Meleine M, Gelot A, Piche T, Dapoigny M, Muller E, et al. Review article: associations between immune activation, intestinal permeability and the irritable bowel syndrome. Aliment Pharmacol Ther. 2012;36(11-12):1009-31.
10. Camilleri M, Lasch K, Zhou W. Irritable bowel syndrome: methods, mechanisms, and pathophysiology. The confluence of increased permeability, inflammation, and pain in irritable bowel syndrome. Am J Physiol Gastrointest Liver Physiol. 2012;303(7):G775-85.
11. Scully P, McKernan DP, Keohane J, Groeger D, Shanahan F, Dinan TG, et al. Plasma cytokine profiles in females with irritable bowel syndrome and extra-intestinal co-morbidity. Am J Gastroenterol. 2010;105(10):2235-43.
12. Ortiz-Lucas M, Saz-Peiro P, Sebastian-Domingo JJ. Irritable bowel syndrome immune hypothesis. Part one: the role of lymphocytes and mast cells. Rev Esp Enferm Dig. 2010;102(11):637-47.
13. Zhu H, Lei X, Liu Q, Wang Y. Interleukin-10-1082A/G polymorphism and inflammatory bowel disease susceptibility: a metaanalysis based on 17,585 subjects. Cytokine. 2013;61(1):146-53.
14. Banchereau J, Pascual V, O'Garra A. From IL-2 to IL-37: the expanding spectrum of anti-inflammatory cytokines. Nat Immunol. 2012;13(10):925-31.
15. Vignali DA, Kuchroo VK. IL-12 family cytokines: immunological playmakers. Nat Immunol. 2012;13(8):722-8.
16. Barreau F, Ferrier L, Fioramonti J, Bueno L. New insights in the etiology and pathophysiology of irritable bowel syndrome: contribution of neonatal stress models. Pediatr Res. 2007;62(3):240-5.
17. Li X, Kan EM, Lu J, Cao Y, Wong RK, Keshavarzian A, et al. Combat-training increases intestinal permeability, immune activation and gastrointestinal symptoms in soldiers. Aliment Pharmacol Ther. 2013;37(8):799-809.
18. Catassi C, Pierani P, Natalini G, Gabrielli O, Coppa GV, Giorgi PL. Clinical application of a simple HPLC method for the sugar intestinal permeability test. J Pediatr Gastroenterol Nutr. 1991;12(2):209-12.
19. Shulman RJ, Schanler RJ, Lau C, Heitkemper M, Ou CN, Smith EO. Early feeding, antenatal glucocorticoids, and human milk decrease intestinal permeability in preterm infants. Pediatr Res. 1998;44:519-23.
20. McOmber ME, Ou CN, Shulman RJ. Effects of timing, sex, and age on site-specific gastrointestinal permeability testing in children and adults. J Pediatr Gastroenterol Nutr. 2010;50(3):269-75.
21. O'Mahony L, McCarthy J, Kelly P, Hurley G, Luo F, Chen K, et al. Lactobacillus and bifidobacterium in irritable bowel syndrome: symptom responses and relationship to cytokine profiles. Gastroenterology. 2005;128(3):541-51.
22. Reilly MC, Zbrozek AS, Dukes EM. The validity and reproducibility of a work productivity and activity impairment instrument. Pharmacoeconomics. 1993;4(5):353-65.
23. Jarrett ME, Cain KC, Burr RL, Hertig VL, Rosen SN, Heitkemper MM. Comprehensive self-management for irritable bowel syndrome: randomized trial of in-person vs. combined in-person and telephone sessions. Am J Gastroenterol. 2009;104(12):3004-14.
24. Derogatis L. BSI: Brief Symptom Inventory; administration, scoring and procedures manual. 4th ed. Minneapolis: National Computer Systems; 1993.
25. Camilleri M, Lasch K, Zhou W. The confluence of increased permeability, inflammation, and pain in irritable bowel syndrome. Am J Physiol Gastrointest Liver Physiol. 2012;303:G775-85.
26. Zhou Q, Zhang B, Verne GN. Intestinal membrane permeability and hypersensitivity in the irritable bowel syndrome. Pain. 2009;146(1-2):41-6.
27. Marshall JK, Thabane M, Garg AX, Clark W, Meddings J, Collins SM. Intestinal permeability in patients with irritable bowel syndrome after a waterborne outbreak of acute gastroenteritis in Walkerton, Ontario. Aliment Pharmacol Ther. 2004;20(11-12): 1317-22.
28. Dunlop SP, Hebden J, Campbell E, Naesdal J, Olbe L, Perkins AC, et al. Abnormal intestinal permeability in subgroups of diarrhea-predominant irritable bowel syndromes. AmJ Gastroenterol. 2006;101(6):1288-94.
29. Kamada N, Seo SU, Chen GY, Nunez G. Role of the gut microbiota in immunity and inflammatory disease. Nat Rev Immunol. 2013;13(5):321-35.
30. Kaji I, Yasuoka Y, Karaki S, Kuwahara A. Activation of TRPA1 by luminal stimuli induces EP4-mediated anion secretion in human and rat colon. Am J Physiol Gastrointest Liver Physiol. 2012;302(7):G690-701.
31. Saulnier DM, Riehle K, Mistretta TA, Diaz MA, Mandal D, Raza S, et al. Gastrointestinal microbiome signatures of pediatric patients with irritable bowel syndrome. Gastroenterology. 2011;141(5):1782-91.
32. Langhorst J, Junge A, Rueffer A, Wehkamp J, Foell D, Michalsen A, et al. Elevated human beta-defensin-2 levels indicate an activation of the innate immune system in patients with irritable bowel syndrome. Am J Gastroenterol. 2009;104(2):404-10.
33. Suzuki T. Regulation of intestinal epithelial permeability by tight junctions. Cellular and molecular life sciences. CMLS. 2013;70(4):631-59.
34. Chang L, Adeyemo M, Karagiannides I, Videlock EJ, Bowe C, Shih W, et al. Serum and colonic mucosal immune markers in irritable bowel syndrome. Am J Gastroenterol. 2012;107(2):262-72.
35. Schmulson M, Pulido-London D, Rodriguez O, Morales-Rochlin N, Martinez-Garcia R, Gutierrez-Ruiz MC, et al. Lower serum IL-10 is an independent predictor of IBS among volunteers in Mexico. Am J Gastroenterol. 2012;107(5):747-53.
36. Kindt S, Van Oudenhove L, Broekaert D, Kasran A, Ceuppens JL, Bossuyt X, et al. Immune dysfunction in patients with functional gastrointestinal disorders. Neurogastroenterol Motil. 2009;21(4):389-98.
37. Hughes PA, Harrington AM, Castro J, Liebregts T, AdamB, Grasby DJ, et al. Sensory neuro-immune interactions differ between irritable bowel syndrome subtypes. Gut. 2012;62:1456-65.
38. Liebregts T, Adam B, Bredack C, Roth A, Heinzel S, Lester S, et al. Immune activation in patients with irritable bowel syndrome. Gastroenterology. 2007;132(3):913-20.
39. Hua MC, Lai MW, Kuo ML, Yao TC, Huang JL, Chen SM. Decreased interleukin-10 secretion by peripheral blood mononuclear cells in children with irritable bowel syndrome. J Pediatr Gastroenterol Nutr. 2011;52(4):376-81.
40. Chogle A, Sztainberg M, Bass L, Youssef NN, Miranda A, Nurko S, et al. Accuracy of pain recall in children. J Pediatr Gastroenterol Nutr. 2012;55(3):288-91.
41. Engsbro AL, Simren M, Bytzer P. The Rome II and Rome III criteria identify the same subtype-populations in irritable bowel syndrome: agreement depends on the method used for symptom report. Neurogastroenterol Motil. 2012;24(7):604-11, e266.
42. Weinland SR, Morris CB, Hu Y, Leserman J, Bangdiwala SI, Drossman DA. Characterization of episodes of irritable bowel syndrome using ecological momentary assessment. Am J Gastroenterol. 2011;106(10):1813-20.